Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry
- 771 Downloads
To describe demographic, genetic, and clinical characteristics of patients with neuronopathic Gaucher disease (NGD).
All patients enrolled in the Neurological Outcomes Subregistry of the International Collaborative Gaucher Group (ICGG) Gaucher Registry as of June 2007 were identified.
The study cohort comprised 131 patients from 17 countries who were enrolled in the Neurological Outcomes Subregistry. The onset of neurological manifestations had occurred before 2 years of age in 47% (61 out of 131 patients), 2 years of age or older in 41% (54 out of 131), and could not be ascertained in the remaining 12% (16 out of 131). The most common manifestations were inability to look to the extreme up or down (45%, 55 out of 123), abnormally slow object tracking (43%, 53 out of 123), convergent squint (36%, 44 out of 121), and ataxia (15 to 20%, 18–27 out of 117). Seizures were reported in 19 out of 122 patients (16%), and myoclonic seizures were reported in 3 out of 121 patients (2%). The most common genotypes were L444P/L444P (76 out of 108, 70%), L444P/D409H (9 out of 108, 8%), D409H/D409H (8 out of 108, 7%), and L444P/rare allele (6 out of 108, 6%); full sequencing was not performed in all patients.
Neurological manifestations of GD often begin to appear before the age of 2 years. The most common neurological signs and manifestations are brainstem abnormalities and fine motor dysfunction. The most common genotype is L444P/L444P.
KeywordsNeurological Outcome Gauche Disease Neurological Manifestation Gauche Disease Patient Genzyme Corporation
International Collaborative Gaucher Group
neuronopathic Gaucher disease
We would like to thank the patients with neuronopathic Gaucher disease and their physicians and health care personnel who submit data to the Neurological Outcomes Subregistry, the Gaucher Registry support team at Genzyme Corporation, Andrea Gwosdow, Ph.D., for assistance in preparing the manuscript, Robert Brown (Genzyme Corporation) for graphic design of the figure, Michael Yeh, M.D. (Genzyme Corporation), for critical review of the manuscript and Pramod Mistry, M.D., Ph.D., for providing GBA1 gene sequencing for the Egyptian type 3 patients.
- Beutler E, Grabowski GA (1995) Gaucher disease. In: Scriver CH, Beaudet AL, Sly WS, Valle D (eds), The metabolic and molecular bases of inherited disease. McGraw Hill, New YorkGoogle Scholar
- Grabowski G, Kolodny E, Weinreb N et al (2006) Gaucher disease: phenotypic and genetic variation. Chapter 146.1. The Online Metabolic & Molecular Bases of Inherited Disease. New York: McGraw-Hill Online: http://genetics.accessmedicine.com/serverjava/Arknoid/amed/mmbid/co_chapters/ch146.1/ch146.1_p01.html
- Khalifa AS, Fateen E, Tantawy AAG et al (1999) Phenotype-genotype expression of Gaucher disease in Egyptian infants and children. Egyptian J Pediatr 16:631–653Google Scholar
- Ludwig J (1979) Current methods of autopsy practice. Saunders, Philadelphia, PAGoogle Scholar
- STROBE statement. Strengthening the reporting of observational studies in epidemiology. Available at: http://www.strobe-statement.org. Accessed 1 November 2008